Literature DB >> 9336346

The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells.

H Yokoshiki1, Y Katsube, M Sunagawa, N Sperelakis.   

Abstract

Levosimendan, a new Ca++-sensitizing and positive inotropic agent, was reported to act as a coronary vasodilator and protect ischemic myocardium. To elucidate the mechanisms of these actions, the possible electrophysiological effects of levosimendan on isolated rat ventricular cells were examined by the patch-clamp technique with whole-cell and single-channel recordings. Levosimendan (3 and 10 microM) markedly shortened action potential duration and activated an outward current at potentials positive to -70 mV. The increased current was abolished by glibenclamide, a blocker of the ATP-sensitive K+ (K[ATP]) current. Stimulation of K[ATP] current was dose dependent, with an EC50 value of 4.7 microM; a maximal effect occurred at 30 microM. The L-type Ca++ current was not affected by levosimendan (0.2-10 microM). In single-channel current recording in open cell-attached patches, K[ATP] channels, which had been inhibited by 0.3 mM ATP, were activated by levosimendan. However, levosimendan did not stimulate the K[ATP] channels that exhibited high spontaneous activity in ATP-free solution. Levosimendan also could not stimulate K[ATP] channels that had rundown in ATP-free solution. However, levosimendan could stimulate rundown K[ATP] channels that were reactivated by nucleotide diphosphates. K[ATP] channels inhibited by 0.5 mM AMP-PNP, a nonhydrolyzable ATP analog, were not stimulated by levosimendan; however, the channels were stimulated by levosimendan in the presence of 30 to 50 microM ADP. Levosimendan stimulates cardiac K[ATP] channels that are suppressed by intracellular ATP. It appears that levosimendan acts synergistically with nucleotide diphosphates. These properties of levosimendan may help protect ischemic myocardium because activation of K[ATP] channels by levosimendan would likely occur in ischemic regions in which intracellular ADP concentration is increased and intracellular ATP concentration is decreased.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336346

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

Review 1.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 2.  Regulation of ion channels in myocardial cells and protection of ischemic myocardium.

Authors:  N Sperelakis; M Sunagawa; H Yokoshiki; T Seki; M Nakamura
Journal:  Heart Fail Rev       Date:  2000-06       Impact factor: 4.214

3.  The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Authors:  Nóra Erdei; Zoltán Papp; Piero Pollesello; István Edes; Zsolt Bagi
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

4.  A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart.

Authors:  E F du Toit; A Genis; L H Opie; P Pollesello; A Lochner
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

5.  Levosimendan restores the positive force-frequency relation in heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Hideo Tachibana; William C Little; Che-Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

6.  Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model.

Authors:  E du Toit; D Hofmann; J McCarthy; C Pineda
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

7.  Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.

Authors:  Tsuyoshi Hayashi; Maxime Jean; Huachao Huang; Sydney Simpson; Netty G Santoso; Jian Zhu
Journal:  Antiviral Res       Date:  2017-08-24       Impact factor: 5.970

8.  Treatment of acute heart failure using levosimendan for a patient with dilated cardiomyopathy, chronic renal failure, and hypertension.

Authors:  Pablo Lobo Martínez; Ignacio Oulego Erroz; Sandra Gautreux Minaya; Luis Miguel Rodríguez Fernández
Journal:  Pediatr Cardiol       Date:  2011-07-10       Impact factor: 1.655

9.  Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction.

Authors:  Georgios Papadopoulos; Nikolaos G Baikoussis; Petros Tzimas; Stavros N Siminelakis; Menelaos Karanikolas
Journal:  J Cardiothorac Surg       Date:  2010-03-02       Impact factor: 1.637

10.  Newer treatments for decompensated heart failure: focus on levosimendan.

Authors:  Ferenc Follath
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.